Table 1.

Published articles on the pharmacological treatment of male osteoporosis

Ref.	No. cases	Follow-up	Type of trial	BMD increase	Outcome parameter	BTMs
Bisphosphonates treatment
Orwoll et al[108]	241	2 yr	Double-blind	+	Vertebral fracture	NS
Ringe et al[110]	316	1 yr	Open label, randomized	+	Vertebral fracture	NS
Ringe et al[109]	90	2 yr	Comparative	+	NS	NS
Boonen et al[111]	284	2 yr	Double-blind	+	Vertebral fracture	+
Orwoll et al[112]	132	1 yr	Placebo-controlled, randomized	+	NS	+
Lyles et al[114]	2127	1.9 yr	Double-blind	+	Vertebral fracture	NS
Adachi et al[116]	2127	3 yr	Double-blind	NS	HRQoL improve	NS
Sambrook et al[115]	265	1 yr	Double-blind	+	NS	NS
Genant et al[113]	89	1 yr	Placebo-controlled	+	NS	NS
Anabolic treatment
Orwoll et al[121]	437	11 mo	Randomized	+	NS	NS
Kaufman et al[122]	325	42 mo	Placebo-controlled	+	Vertebral fracture	NS
Leder et al[124]	17	42 mo	Prospective	+	NS	+
Finkelstein et al[123]	42	30 mo	Randomized controlled	+	NS	+
Testosterone treatment
Finkelstein et al[125]	21	31 mo	Prospective	+	NS	NS
Katznelson et al[126]	36	18 mo	Controlled	+	NS	+
Amory et al[127]	70	36 mo	Randomized	+	NS	NS
Benito et al[128]	10	24 mo	Prospective	+	NS	NS
Monoclonal antibody therapy
Smith et al[131]	1468	36 mo	Double-blind	+	NS	NS
Smith et al[133]	1468	36 mo	Double-blind	NS	NS	+
Toremifene
Smith et al[134]	847	2 yr	Placebo-controlled	NS	Vertebral fracture	NS

Bone mineral density (BMD) increase mean: Sign +: Increase of BMD. Outcome parameter meaning: (1) Vertebral fracture (decreases); and (2) Health-related quality of life improve the health-related quality of life. BTMs: Improvement of biochemical markers; HRQoL: Health-related quality of life. NS: Not studied.